| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6552065 | SECURA | Deacetylase inhibitors |
Aug, 2021
(2 years ago) | |
| US6833384 | SECURA | Deacetylase inhibitors |
Sep, 2021
(2 years ago) | |
| US7989494 | SECURA | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
Jan, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7067551 | SECURA | Deacetylase inhibitors |
Aug, 2021
(2 years ago) | |
| US8883842 | SECURA | Use of HDAC inhibitors for the treatment of myeloma |
Jun, 2028
(4 years from now) | |
Farydak is owned by Secura.
Farydak contains Panobinostat Lactate.
Farydak has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Farydak are:
- US7067551
- US6552065
- US6833384
Farydak was authorised for market use on 23 February, 2015.
Farydak is available in capsule;oral dosage forms.
Farydak can be used as treatment of multiple myeloma, in combination with bortezomib and dexamethasone.
Drug patent challenges can be filed against Farydak from 23 February, 2019.
The generics of Farydak are possible to be released after 13 June, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 23, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 23, 2022 |
| Orphan Drug Exclusivity(ODE-89) | Feb 23, 2022 |
Drugs and Companies using PANOBINOSTAT LACTATE ingredient
NCE-1 date: 23 February, 2019
Market Authorisation Date: 23 February, 2015
Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone
Dosage: CAPSULE;ORAL
FARYDAK family patents
